Introduction
============

The development of new antibiotics to combat the crisis of antibiotic resistance to potentially life-threatening pathogens has attracted great attention over recent decades.[@b1-ijn-8-1285] Daptomycin, a novel cyclic lipopeptide antibacterial agent, has been used in the treatment of Gram-positive pathogens, including vancomycin-resistant enterococci and methicillin-resistant *Staphylococcus aureus*. Due to its unique chemical structure, which consists of a peptide nucleus with various lipid acyl groups at the N terminus characteristic of each component, daptomycin exerts its antibacterial effect via multiple mechanisms.[@b2-ijn-8-1285] It can disturb amino acid transport through the bacterial cell membrane, block synthesis of the bacterial cell wall, destroy the bacterial cell membrane which then releases its contents, and disrupt the membrane potential via surrounding calcium ions.[@b3-ijn-8-1285],[@b4-ijn-8-1285] Consequently, bacteria cannot easily become resistant to daptomycin. Cubicin^®^ (daptomycin for injection, Cubist Pharmaceuticals Inc, Lexington, MA, USA) is the only approved once-daily treatment available for complex skin and skin structure infections caused by susceptible strains of Gram-positive micro-organisms and *S. aureus* bloodstream infections in the United States. Considering the patient compliance and drug distribution in the target tissues, there is a pressing need to develop new dosage formulations of daptomycin to satisfy a range of therapeutic requirements.

During recent decades, nanotechnology has become increasingly important in medicine because of its remarkable properties arising from the nanosize effect, and has shown superiority over traditional formulations for local topical therapy. For example, liposomes are a versatile drug nanocarrier, have been widely used in systemic therapy, and have shown potential for delivering drugs into multiple layers of the skin.[@b5-ijn-8-1285],[@b6-ijn-8-1285] The mechanism of enhanced skin delivery includes but is not limited to: the cell membrane-like structure of the liposome having good biocompatibility; the small size of liposomes; formation of drug reservoirs in the skin; and specific liposome-skin interactions.[@b6-ijn-8-1285],[@b7-ijn-8-1285] Cevc et al have introduced a further step to create flexible liposomes and transfersomes containing lecithin and cholesterol.[@b8-ijn-8-1285],[@b9-ijn-8-1285] Surface-active agents can be inserted into the lipid bilayers of flexible liposomes and create a "softened" bilayer membrane, thus making liposomes more flexible and permeable than ordinary liposomes.[@b10-ijn-8-1285]--[@b12-ijn-8-1285] The highly deformable membranes of flexible liposomes facilitate their rapid distribution into the skin. Further, the osmotic gradient created by the difference in water concentration between the surface and interior of the skin has been identified as the major driving force for penetration of flexible liposomes into the skin.[@b8-ijn-8-1285]

This study developed daptomycin-loaded flexible nanoliposomes (DAP-FL) for topical skin therapy. The formulation was optimized via response surface methodology. The physicochemical properties of the optimized DAP-FL were characterized, and their bioactivity against *S. aureus* and biofilms was evaluated both in vitro and in vivo. Our results demonstrate the potential of DAP-FL in the treatment of complicated skin and skin structure infections caused by susceptible strains of designated micro-organisms.

Materials and methods
=====================

Materials
---------

Daptomycin (purity \> 98%) was sourced from Melone Pharmaceutical Co (Dalian, People's Republic of China), soy lecithin (purity \> 98%) from Aladdin Asia (Shanghai, People's Republic of China), and sodium cholate (purity \> 98%) from TCI Chemical Reagent Co, Ltd (Tokyo, Japan). Methyl alcohol and acetonitrile (high-pressure liquid chromatography grade) were obtained from Swell Scientific Instruments Co, Ltd., Chengdu, People's Republic of China. All reagents were of analytical grade and used without further purification. The isotonic phosphate-buffered solution used in this study contained 8.01 g/L NaCl, 0.2 g/L KCl, 1.78 g/L Na~2~HPO~4~ · 2H~2~O, and 0.27 g/L KH~2~PO~4~. The pH value was adjusted to 7.4 ± 0.1.

*S. aureus* (ATCC25923) was incubated in tryptic soy broth (Nissui Pharmaceuticals, Tokyo, Japan) at 37°C.[@b13-ijn-8-1285] Six-week-old male BALB/c mice weighing approximately 20 ± 2 g were used in this study, and the mice were raised under specific pathogen-free conditions. All animal experiments were carried out in accordance with the guidelines for animal experiments performed at Southwest University (Chongqing, People's Republic of China).

Preparation of DAP-FL
---------------------

DAP-FL were prepared using a dry film dispersion method. Briefly, soy phosphatidylcholine (264.50 mg) and sodium cholate (15.50 mg) were dissolved in 8 mL of chloroform/ methanol (1/3, v/v) solution and rotary evaporated to form a thin film at 37°C. After complete removal of the organic solvent, 10 mL of phosphate-buffered solution (pH 7.4) containing 20 mg of daptomycin was added to the lipid film as a hydration solution and shaken in a water bath at 150 rpm for one hour. The processing temperature was maintained at 37°C. The suspensions obtained were then sonicated at 800 W (intermittent operation for 10 seconds on and 10 seconds off) for 20 minutes to obtain small and uniform liposome vesicles.

Characterization of DAP-FL
--------------------------

The mean particle size, polydispersity index, and zeta potential of the liposome vesicles were determined using dynamic light scattering (Zetasizer Nano ZS, Malvern, Worcestershire, UK) at 25°C. Before characterization, the samples were further diluted with phosphate-buffered solution to form a liposome suspension with a total lipid concentration of 5 mg/mL. Transmission electron microscopy was used to characterize the morphology of the liposome vesicles using a negative staining method. Samples were pretreated with 2% phosphotungstic acid and then air-dried before measurement.

Encapsulation efficiency and drug-loading of daptomycin
-------------------------------------------------------

The percentage of daptomycin encapsulated in the flexible liposomes was measured in two steps. First, the DAP-FL obtained before chromatographic purification were divided into two equal parts. One part was dialyzed against phosphate-buffered solution overnight, using a dialysis membrane with a molecular cutoff of approximately 10,000 Da. The other part was diluted in the same volume as the first sample. The two samples were then lysed with 0.1% (v/v) Triton X-100, and the daptomycin content was determined using high-pressure liquid chromatography. The entrapment efficiency of DAP-FL (EE ~DAP-FL~, %) was calculated as:
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where W and W~0~ are the daptomycin content in the purified flexible liposomes and the total drug content in the dispersion, respectively.

Percent drug loading in the prepared liposomes (PDL~DAP-FL~ %) was calculated as:
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where W is the daptomycin content in purified flexible liposomes and W~e~ is the total amount of excipients.

Quantification of daptomycin was done using a reverse phase high-pressure liquid chromatography system with an ultraviolet absorbance detector set at 223 nm. The mobile phase consisted of 0.2 M phosphate buffer (pH 5.5)/ acetonitrile (64/36, v/v). A C18 chromatographic column (150 mm × 4.6 mm, 5 μm) was used, with the flow rate set at 0.7 mL per minute at 30°C.[@b14-ijn-8-1285],[@b15-ijn-8-1285]

DAP-FL stability study
----------------------

The DAP-FL were stored as native dispersions at 4°C in a refrigerator. Changes in particle size and polydispersity were determined, and the method used for detection of the leakage rate was similar to that used for determination of encapsulation efficiency as described above.

In vitro skin permeation study
------------------------------

Mouse skin was used as a model membrane for human skin during the permeation studies. Dorsal mouse skin was treated to remove any fatty material, then mounted between the donor and receptor compartments of a modified Franz diffusion cell, with the epidermal side facing the donor compartment.[@b16-ijn-8-1285],[@b17-ijn-8-1285] The effective diffusion area was 2.50 cm^2^, and the volume of the receptor compartment was 50 mL. The receptor compartment was filled with 50 mL of phosphate-buffered solution maintained at 37°C ± 0.5°C and stirred at 100 rpm. One mL of DAP-FL was placed into the donor compartment, and the top of the diffusion cell was covered. At predetermined time intervals (0.5, 1, 2, 4, 6, 8, 12, and 24 hours), one mL of receptor medium was withdrawn and replenished with one mL of fresh medium. The concentration of daptomycin was analyzed by high-pressure liquid chromatography, and the cumulative amount of daptomycin permeated was plotted against time.

In vitro pharmacodynamic study
------------------------------

The antibacterial activity of the daptomycin formulation after permeation into the skin was evaluated first in vitro. The same device with the modified Franz diffusion cell described above was used, varying the point at which bacteria or a biofilm of *S. aureus* was added to the receptor compartment.

Briefly, *S. aureus* was inoculated into culture and grown for 8 hours until the bacteria reached the stationary phase. One mL of bacterial suspension was withdrawn, and bacteria were recovered from the culture using centrifugation. *S. aureus* bacteria were then added into the receptor compartment of the Franz diffusion cell. The number of bacteria in the samples withdrawn from the receptor medium at predetermined time intervals was quantified by counting colony-forming units.

For the antibiofilm assay, *S. aureus* bacteria were inoculated in tryptic soy broth (with 1 cm^2^ pieces of silicone membrane) culture and grown for 7 days to form mature biofilms of *S. aureus* bacteria on the silicone membranes.[@b13-ijn-8-1285] One piece of mature biofilm was placed into the Franz diffusion cell with 50 mL of phosphate-buffered solution and maintained at 37°C ± 0.5°C. After 24 hours, the silicone membrane was removed and the shape of the biofilms on the membrane was observed using scanning electron microscopy.[@b18-ijn-8-1285] The bacterial count was quantified by counting the number of colony-forming units per piece of membrane after shaking *S. aureus* from the biofilms using sonication.[@b19-ijn-8-1285]

Pharmacokinetic study in vivo
-----------------------------

The mice were lightly anesthetized using pentobarbitone (35 mg/kg intraperitoneally with additional boluses as needed to maintain anesthesia). Hair from a 4 cm^2^ dorsal area was removed using electric clippers and the rest of the hair was eliminated using 4% sodium sulfide solution followed by cleaning with phosphate buffer. DAP-FL (containing daptomycin 50 mg/kg) was administered to the dorsal area. After administration, samples of the dermis, subcutaneous tissue, fascia, superficial muscle, and deep muscle were collected at predetermined time intervals, and weighed and stored in a cool place. The samples were then homogenized in phosphate buffer and centrifuged. The resulting supernatants from the tissue samples were treated with acetonitrile to precipitate the proteins. After centrifugation, the supernatants were concentrated using a pressure-blowing concentrator and analyzed using high-pressure liquid chromatography. The data are expressed as mean ± standard deviation (n = 5).

Pharmacodynamic study in vivo
-----------------------------

The mice were anesthetized using pentobarbitone. Hair on a 4 cm^2^ dorsal area was shaved and the skin was cleaned with phosphate buffer. One subcutaneous pocket was made on each side of the median line by a 1.2 cm incision. Prior to implantation, a silicone membrane (1 cm^2^) was kept in tryptic soy broth within the *S. aureus* culture for 7 days to form the mature biofilms, and the silicone membranes were then implanted into the pockets[@b20-ijn-8-1285] ([Figure 1](#f1-ijn-8-1285){ref-type="fig"}). One day after implantation, the mice were randomly divided into three groups and treated with saline solution (blank control group), daptomycin solution at 50 mg/kg (positive control group), and DAP-FL at 50 mg/kg (experimental group). The silicone membranes were retrieved 4 days after administration and imaged by scanning electron microscopy. The number of colony-forming units per silicone membrane was quantified by counting after shaking *S. aureus* from the biofilms ultrasonically.

Results
=======

Preparation and optimization of DAP-FL
--------------------------------------

Three possible factors were found to influence the preparation and quality of the daptomycin formulation in the preliminary studies. To obtain optimal levels of these variables and obtain the best system performance simultaneously, response surface methodology was used to optimize the most important parameters involved in the preparation of DAP-FL. Design Expert version 8.1 software was used to design the experimental groups and analyze the study results. Drug loading was used as the evaluation index.

The study results were fitted to a full second-order model, and the following equation was obtained:
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where A (lecithin to sodium cholate ratio), B (lipid to drug ratio), C (time of ultrasonic treatment), AB, AC, A^2^, B^2^, and C^2^ were significant model terms. A Pred R (predeterminated relative coefficient) -- squared of 0.8826 is in reasonable agreement with the Adj R (Adjusted relative coefficient) -- squared of 0.9770. An adequate precision of 24.316 indicates an adequate signal to noise ratio. Therefore, the model obtained is credible and could be used to navigate the design space and for practical predictions. [Figure 2](#f2-ijn-8-1285){ref-type="fig"} provides a visual representation of the effect of interactions between critical factors on drug loading. The optimal preparation conditions for DAP-FL were identified as a lecithin to sodium cholate ratio of 17:1 (w/w), a lipid to drug ratio of 14:1 (w/w), and treatment with ultrasound for 20 minutes.

Characterization of DAP-FL
--------------------------

The mean vesicle diameter was 55.4 nm ([Figure 3](#f3-ijn-8-1285){ref-type="fig"}) and the zeta potential was −15.1 mV. Mean entrapment efficiency was 87.85% ± 2.15%, and the percentage drug loading was 5.61% ± 0.14%. Importantly, DAP-FL vesicle size and size distribution remained almost unchanged, and no obvious daptomycin leakage occurred after storage at 4°C in a refrigerator for 2 months ([Table 1](#t1-ijn-8-1285){ref-type="table"}), indicating that the formulation has good stability. For high-pressure liquid chromatographic detection of daptomycin in the formulation, the calibration curve was y = 10347x − 42667, which was linear over a concentration range of 0.03--4.00 μg/mL and had a correlation coefficient \> 0.999.

Skin permeation study in vitro
------------------------------

As shown in [Figure 4](#f4-ijn-8-1285){ref-type="fig"}, the cumulative percentage of daptomycin permeated through the skin was greater than 25% within the first 2 hours (37.35% ± 3.02%), and the cumulative amount of daptomycin permeated through the skin was (51.72 ± 9.37) μg/cm^2^ \*5 = 258.6 ± 46.85 μg/cm^2^ directly. After 12 hours, almost all of the daptomycin had penetrated through the skin, with a cumulative percentage of 96.28% ± 0.70% and a quantity of (132.23 ± 17.73) μg/cm^2^ \*5 = 661.15 ± 88.65 μg/cm^2^ directly. These results were further analyzed using Drug and Statistics Software version 3.0 (Mathematical Pharmacology Professional Committee of China), fitted to a quadratic model, and the following expression was obtained:
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where T is time and Y is quantity of cumulative permeation at time T (r = 0.994).

Pharmacodynamic study in vitro
------------------------------

The spread-plate method (with a dilution rate of 10) was conducted to count the number of *S. aureus* bacteria at each time point for the experimental and control groups. As shown in [Figure 5](#f5-ijn-8-1285){ref-type="fig"}, DAP-FL had a remarkable bacteriostatic effect compared with the control group. The possible effect of DAP-FL on biofilms after transdermal flux was also investigated. The biofilms were observed by scanning electron microscopy, which gives very clear images. The number of *S. aureus* cells embedded in the biofilms was counted after ultrasonic shaking. Damaged *S. aureus* biofilms were observed in the experimental group with broken pieces scattered on the silicone membrane, whereas the biofilms in the control group were unaffected. Very few viable *S. aureus* cells were observed in the experimental group, while the populations of *S. aureus* in the control group reached a 10^8^ order of magnitude ([Figure 5A](#f5-ijn-8-1285){ref-type="fig"}).

Pharmacokinetic study in vivo
-----------------------------

[Figure 6](#f6-ijn-8-1285){ref-type="fig"} shows the distribution of daptomycin in different layers of mouse skin tissue and structures on the dorsal area, including the maximum concentrations of daptomycin reached within 2 hours for all five skin layers. For the dermis and subcutaneous tissues, the maximum concentrations were 194.55 ± 12.48 μg/g (4.86% of total dose) and 175.30 ± 11.54 μg/g (4.61% of total dose), respectively. The daptomycin concentration in these two layers was maintained at over 40 μg/g for 12 hours. In deep muscles, the maximum concentration reached more than 100 μg/g (100.40 ± 9.54 μg/g) and remained above a concentration of 40 μg/g for more than 6 hours. Considering the high potency of daptomycin against *S. aureus* (minimum inhibitory concentration 0.25--0.50 μg/mL),[@b21-ijn-8-1285] the amounts of permeated and accumulated drug were theoretically sufficient to inhibit the growth of pathogenic bacteria. The main pharmacokinetic parameters were then calculated using noncompartmental analysis (Drug and Statistics Software version 3.0) as shown in [Table 2](#t2-ijn-8-1285){ref-type="table"}.

Pharmacodynamic study in vivo
-----------------------------

As expected, the same pharmacodynamic trends were observed in vivo as in vitro. We also observed the shape of the biofilms and counted the number of viable *S. aureus* bacteria in these biofilms using scanning electron microscopy and the spread-plate method, respectively. The results are shown in [Figure 7](#f7-ijn-8-1285){ref-type="fig"}. On day 4 following administration, the biofilm surfaces in the blank control group were thickly dotted with viable *S. aureus*, while both the experimental group and the positive control group showed only scattered *S. aureus* on damaged biofilms. When counting cell numbers, there was no significant difference (*P* \> 0.05) between the experimental group (transdermal delivery by flexible nanoliposomes) and the positive control group (intravenous injection).

Discussion
==========

In recent decades, multidrug-resistant bacteria have posed a serious challenge to development of new antibiotic agents. Accordingly, there is an urgent need to identify new drug resistance mechanisms as part of research and development concerning novel antibiotic molecular entities. Due to its unique functional mechanism, daptomycin is currently considered to be a promising agent for the treatment of Gram-positive infections.[@b22-ijn-8-1285] Cubicin, a daptomycin solution for injection, has been used clinically. However, with respect to the detailed requirements for specific diseases and syndromes, an appropriate route of administration and vehicle for drug delivery are needed, to enhance accumulation of the drug further in target tissues and to improve the outcome of antibacterial treatment. Therefore, development of novel formulations for daptomycin may expand its range of applications, with potential clinical significance. Effective drug permeation and local distribution are important in the treatment of topical skin infections. Flexible nanoliposomes can adapt to the environment and diffuse effectively through the skin and underlying tissues.

In the present study, optimized DAP-FL had a particle small size with a narrow size distribution, and could achieve high drug loading with excellent stability. The in vitro skin permeation study indicated that flexible nanoliposomes can diffuse rapidly and efficiently into the skin and inhibit pathogen growth significantly in a simulated receptor compartment. Further, pharmacokinetic data gathered from tissues suggest that DAP-FL can permeate the skin and underlying tissues, reaching a maximum concentration rapidly and maintaining high drug levels for several hours (compared with the high potency of daptomycin against pathogens). The dose of daptomycin used in this study was based on the medical directions for Cubicin, which set the dose at 4 mg/kg for treatment of complicated skin and skin structure infections in humans; we then converted the human dose to an equivalent mouse dose. This algorithm, based on bioequivalence between humans and mice, was devised by Reagan-Shaw et al.[@b23-ijn-8-1285] It was concluded that the human dose (mg/kg) was equivalent to the animal dose (mg/kg) multiplied by the animal K*~m~*/human K*~m~*, where the human K*~m~* = 37 and the mouse K*~m~* = 3. Accordingly, the mouse K*~m~* (mg/kg) of daptomycin = 4 mg/kg × 37/3 ≈ 50 mg/kg.

In the clinical setting, many antibiotic drugs sterilize incompletely because of the presence of biofilm which is an aggregate of bacteria in which cells adhere to inactive objects or living surfaces.[@b24-ijn-8-1285],[@b25-ijn-8-1285] These adherent bacteria have a certain structure and can be protected by a self-produced matrix of extracellular polymeric substances. Once a bacterium forms a mature biofilm, it can resist host immunity and sterilization by antibiotic agents.[@b24-ijn-8-1285] Daptomycin can be used for the treatment of biofilm, where transdermal flux of DAP-FL shows potent bacteriostatic activity, demonstrated by both in vitro and in vivo studies. Considering the interactions between liposomal lipid bilayers and natural biomembranes, it is expected that flexible nanoliposomes may enable greater penetration of antibacterial agents into biofilm.[@b26-ijn-8-1285]

In conclusion, novel DAP-FL were prepared, which can diffuse efficiently into skin and show both anti-infective and antibiofilm activity against specific pathogens within the skin and underlying structures. Thus, our research may provide useful information for potential clinical applications using daptomycin as an alternative delivery approach to current intravenous administration.
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![Three-dimensional models of the response surface for optimization of daptomycin-loaded flexible liposomes. (**A**) Effects of lipid/drug and lipid/sodium cholate on drug loading; (**B**) three-dimensional model of effects of lipid/drug and lipid/sodium cholate on drug loading; (**C**) effects of lipid/drug and duration of sonication treatment on drug loading; (**D**) three-dimensional model of effects of lipid/drug and duration of sonication treatment on drug loading.](ijn-8-1285f2){#f2-ijn-8-1285}

![Determination of daptomycin-loaded flexible liposomes by dynamic light scattering (**A**) and transmission electron microscopy (**B**).](ijn-8-1285f3){#f3-ijn-8-1285}

![Cumulative in vitro permeation of daptomycin-loaded flexible liposomes. (**A**) Quantity of cumulative permeation and (**B**) percentage of cumulative permeation of daptomycin from daptomycin-loaded flexible liposomes.\
**Note:** Data are presented as the mean ± standard deviation (n = 3).](ijn-8-1285f4){#f4-ijn-8-1285}

![Bacteriostatic effect of daptomycin-loaded flexible liposomes in vitro. (**A**) Inhibition of pathogen growth by daptomycin-loaded flexible liposomes; (**B**) scanning electron micrographs of silicone membrane; (**C**) scanning electron micrographs for the blank control; and (**D**) scanning electron micrographs for the experimental group.](ijn-8-1285f5){#f5-ijn-8-1285}

![Pharmacodynamic study of skin and underlying structures. (**A**) Distribution of daptomycin in dermis; (**B**) subcutaneous distribution of daptomycin; (**C**) distribution of daptomycin in fascia; (**D**) distribution of daptomycin in superficial muscle; (**E**) distribution of daptomycin in deep muscle; and (**F**) percentage of drug accumulated in each layer of skin tissue and structures at time of peak concentration.\
**Note:** Data are presented as the mean ± standard deviation (n = 5).](ijn-8-1285f6){#f6-ijn-8-1285}

![Pharmacodynamic study in vivo on day 4 following administration. (**A**) Scanning electron micrographs of blank control group; (**B**) scanning electron micrographs of positive control group; (**C**) scanning electron micrographs of experimental group; and (**D**) number of viable *Staphylococcus aureus* bacteria remaining in each treatment group.](ijn-8-1285f7){#f7-ijn-8-1285}

###### 

Characterization of stability of daptomycin-loaded flexible liposomes

  Time      Size (nm)   PDI     DAP leakage (%)
  --------- ----------- ------- -----------------
  0 day     55.40       0.150   --
  30 days   56.66       0.167   0.57 ± 0.15
  60 days   58.76       0.173   1.73 ± 0.24

**Note:** Data are shown as the mean ± standard deviation (n = 3).

**Abbreviations:** DAP, daptomycin; PDI, polydispersity index.

###### 

Main pharmacokinetic parameters for daptomycin-loaded flexible liposomes after topical administration

  Parameters   Unit         Dermis     Fascia     Subcutaneous tissue   Superficial muscle   Deep muscle
  ------------ ------------ ---------- ---------- --------------------- -------------------- -------------
  AUC(0-t)     μg/g\*h      1353.013   751.85     1391.725              1262.718             803.993
  AUC(0-∞)     μg/g\*h      1722.585   759.564    1501.103              1552.265             1252.495
  AUMC(0-t)    h\*h\*μg/g   9732.3     5368.513   11592.013             11162.815            6371.033
  AUMC(0-∞)    h\*h\*μg/g   25170.76   5588.706   15190.447             22087.614            31735.801
  MRT(0-t)     h            7.193      7.14       8.329                 8.84                 7.924
  MRT(0-∞)     h            14.612     7.358      10.12                 14.229               25.338
  λz           1/h          0.056      0.22       0.112                 0.073                0.031
  t1/2         h            12.317     3.15       6.167                 9.515                22.56
  Cmax         μg/g         190.55     95.2       170.2                 120.7                95.4

**Abbreviations:** t~1/2~, biological half life; AUC, area under Concentration-time curve; AUMC, area under the first moment of the plasma concentration-time curve. MRT, Mean Retention Time; t~1/2~, biological half life; C~max~, maximum concentration.
